Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2017, Article ID 7938216, 9 pages
Research Article

Metabolomic Signature of Coronary Artery Disease in Type 2 Diabetes Mellitus

1Herz- und Diabeteszentrum NRW, Ruhr-Universitaet Bochum, Diabeteszentrum, 32545 Bad Oeynhausen, Germany
2Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, 85764 Neuherberg, Germany
3Institute of Epidemiology II, Helmholtz Zentrum München, 85764 Neuherberg, Germany
4Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, 85764 Neuherberg, Germany
5Institute of Experimental Genetics, Life and Food Science Center Weihenstephan, Technische Universität München, 85354 Freising, Germany
6German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany

Correspondence should be addressed to Bernd Stratmann; ed.wrn-zdh@nnamtartsb

Received 9 August 2016; Revised 1 December 2016; Accepted 20 December 2016; Published 1 March 2017

Academic Editor: Qian Li

Copyright © 2017 Bernd Stratmann et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Coronary artery disease (CAD) is a common complication of type 2 diabetes mellitus (T2D). This case-control study was done to identify metabolites with different concentrations between T2D patients with and without CAD and to characterise implicated metabolic mechanisms relating to CAD. Fasting serum samples of 57 T2D subjects, 26 with (cases) and 31 without CAD (controls), were targeted for metabolite profiling of 163 metabolites. To assess the association between metabolite levels and CAD, partial least squares (PLS) analysis and multivariate logistic regression analysis with adjustment for CAD risk factors and medications were performed. We observed a separation of cases and controls with two classes of metabolites being significantly associated with CAD, including phosphatidylcholines, and serine. Four metabolites being independent from the common CAD risk factors displaying best separation between cases and controls were further selected. Addition of the metabolite concentrations to risk factor analysis raised the area under the receiver-operating-characteristic curve from 0.72 to 0.88 (), providing improved sensitivity and specificity for CAD classification. Serum phospholipid and serine levels independently discriminate T2D patients with and without CAD. Oxidative stress and reduced antioxidative capacity lead to lower metabolite concentrations probably due to changes in membrane composition and accelerated phospholipid degradation.